Satellos Announces Upcoming Presentations at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference

Rhea-AI Summary

Satellos Bioscience Inc. announced a late-breaking oral and poster presentation at the 2024 Muscular Dystrophy Association Conference. The presentations focus on small molecule therapeutic approaches targeting muscle diseases, including Duchenne. Dr. Phil Lambert, the Chief Scientific Officer, will present SAT-3247, an oral inhibitor targeting AAK1 for muscle regeneration. The Company aims to improve muscle treatment through innovative therapies.

TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced a late-breaking oral presentation and a poster presentation at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 3-6 in Orlando.

Poster Presentation
Title: Therapeutic Restoration of Muscle Regeneration in Duchenne
Poster #: S46
Date: Sunday, March 3, 2024
Time: 6:00PM – 8:00PM EST

Oral Presentation
Title: SAT-3247: An Oral Small Molecule Inhibitor Targeting AAK1, a Critical Effector of Skeletal Muscle Regeneration
Date: Wednesday, March 6, 2024
Time: 12:30 PM ET
Presenter: Phil Lambert, Ph.D., Chief Scientific Officer, Satellos

Copies of the presentation and poster will be available after each session on the Events & Presentations page located at: https://ir.satellos.com/events-and-presentations/default.aspx.

About Satellos Bioscience Inc.
Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated breakthrough research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX™, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, Satellos is building a pipeline of novel therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. Satellos is headquartered in Toronto, Ontario. For more information, visit www.satellos.com.

Notice on Forward-Looking Statements
This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the anticipated benefits to patients from a small molecule treatment for Duchenne; the general benefits of modulating stem cell polarity by administering small molecule drugs; its/their prospective impact on Duchenne patients and muscle regeneration generally and the utility of regenerating muscle by modulating polarity. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are “forward-looking information or statements.” Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “anticipate”, “potential”, “prospective” , “assert” or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry, general market conditions and equity markets, economic factors and management’s ability to manage and to operate the business of the Company generally, and those risks listed in the “Risk Factors” section of Satellos’ prospectus dated May 9, 2023 and Satellos’ Annual Information Form dated April 27, 2023 (both of which are on Satellos’ profile at www.sedarplus.ca). Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward- looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240220717559/en/

Investors: Liz Williams, ir@satellos.com

Business Development: Ryan Mitchell, Ph.D., bd@satellos.com

Media: Jessica Yingling, Ph.D., jessica@litldog.com, +1.858.344.8091

Source: Satellos Bioscience Inc.

FAQ

What is the focus of Satellos Bioscience Inc.'s presentations at the 2024 MDA Conference?

The presentations focus on new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, including Duchenne.

Who will present SAT-3247 at the conference?

Dr. Phil Lambert, the Chief Scientific Officer of Satellos Bioscience Inc., will present SAT-3247, an oral small molecule inhibitor targeting AAK1 for muscle regeneration.

Where can copies of the presentation and poster be found?

Copies of the presentation and poster will be available on the Events & Presentations page located at https://ir.satellos.com/events-and-presentations/default.aspx.